Strategies for evaluating the economic value of drugs in alcohol dependence treatment

Drug and Alcohol Dependence

Volumn 122, Issue 3, 2012, Pages 165-173

  Schwappach, David ^a,b   Popova, Svetlana ^c   Mohapatra, Satya ^c   Patra, Jayadeep ^c   Godinho, Alexandra ^c   Rehm, Jürgen ^a,c,d  

^a WHO Collaborating Centre for Substance Abuse   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF TORONTO   (Canada)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Alcohol dependence; Cost minimization analysis (CMA); Cost utility analysis (CUA); Cost effectiveness analysis (CEA); Economic evaluation; Pharmacotherapy

Indexed keywords

ACAMPROSATE; NALTREXONE;

ALCOHOLISM; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; LIFE EXPECTANCY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW;

ALCOHOLISM; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; HUMANS; NALTREXONE; TAURINE; TREATMENT OUTCOME;

EID: 84859652415     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.08.026     Document Type: Review

References (34)

1. Anderson R. Systematic reviews of economic evaluations: utility or futility. Health Econ. 2010, 19:350-364.
2. Annemans L., Vanoverbeke N., Tecco J., D'Hooghe D. Economic evaluation of campral (acamprosate) compared to placebo in maintaining abstinence in alcohol-dependent patients. Eur. Addict. Res. 2000, 6:71-78.
3. Barbosa C., Godfrey C., Parrott S. Methodological assessment of economic evaluations of alcohol treatment: what is missing?. Alcohol Alcohol. 2010, 45:53-63.
4. Bhandari A., Wagner T. Self-reported utilization of health care services: improving measurement and accuracy. Med. Care Res. Rev. 2006, 63:217-235.
5. Booth B.M., Kirchner J.E., Fortney S.M., Han X., Thrush C.R., French M.T. Measuring use of health services for at-risk drinkers: how brief can you get?. J. Behav. Health Serv. Res. 2006, 33:254-264.
6. Claxton, K., Walker, S., Palmer, S., Sculpher, M., 2010. Appropriate perspectives for health care decisions. Centre for Health Economics, Research Paper 54. Available from: http://www.york.ac.uk/che/publications/in-house/.
7. Del Boca F.K., Noll J.A. Truth or consequences: the validity of self-report data in health services research on addictions. Addiction 2000, 95:S37-S360.
8. Drummond M. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996, 313:275-283. Available from:. http://resources.bmj.com/bmj/authors/checklists-forms/health-economics.
9. Drummond M., O'Brien B., Stoddart G.L., Torrance G.W. Methods for the Economic Evaluation of Health Care Programmes 2005, Oxford University Press, Oxford. 3rd ed.
10. Dunlap L.J., Zarkin G.A., Bray J.W., Millis M., Kivlahan D.R., McKay J.R., Latham P., Tonigan J.S. Revisiting the cost-effectiveness of the COMBINE study for alcohol dependent patients. The patient perspective. Med. Care 2010, 48:306-313.
11. Fleming M.F., Mundt M.P., French M.T., Manwell L.B., Stauffacher E.A., Barry K.L. Brief physician advice for problem drinkers: long term efficacy and benefit-cost analysis. Alcohol. Clin. Exp. Res. 2002, 26:36-43.
12. Gerkens S., Crott R., Cleemput I., Thissen J.-P., Closon M.C., Horsmans Y., Beguin C. Comparison of three instruments assessing the quality of economic evaluations: a practical exercise on economic evaluations of the surgical treatment of obesity. Int. J. Technol. Assess. Health Care 2008, 24:318-325.
13. Godfrey C., Stewart D., Gossop M. Economic analysis of costs and consequences of the treatment of drug misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS). Addiction 2004, 99:697-707.
14. Gunther O., Roick C., Angermeyer M.C., Konig H.H. The EQ-5D in alcohol dependent patients: relationships among health-related quality of life, psychopathology and social functioning. Drug Alcohol Depend. 2007, 86:253-264.
15. Gunther O.H., Roick C., Angermeyer M.C., Konig H.H. Responsiveness of EQ-5D utility indices in alcohol-dependent patients. Drug Alcohol Depend. 2008, 92:291-295.
16. Lee J.M., Chen M.G., Hwang T.C., Yeh C.Y. Effect of cigarette taxes on the consumption of cigarettes, alcohol, tea and coffee in Taiwan. Public Health 2010, 124:429-436.
17. Longo M.C., Henry-Edwards S.M., Humeniuk R.E., Christie P., Ali R.L. Impact of the heroin 'drought' on patterns of drug use and drug-related harms. Drug Alcohol Rev. 2004, 23:143-150.
18. Marshall R., Grayson D., Jorm A., O'Toole B. Are survey measures of medical care utilisation misleading? A comparison of self-reported medical care consumption with actual medical care utilisation. Aust. Health Rev. 2001, 24:91-99.
19. Mortimer D., Segal L. Economic evaluation of interventions for problem drinking and alcohol dependence: do within-family external effects make a difference?. Alcohol Alcohol. 2006, 41:92-98.
20. Palmer A., Neeser K., Weiss C., Brandt A., Comte S., Fox M. The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate. Alcohol Alcohol. 2000, 35:478-492.
21. Poldrugo F., Haeger D.A., Comte S., Walburg J., Palmer A. A critical review of pharmacoeconomic studies of acamprosate. Alcohol Alcohol. 2005, 40:422-430.
22. Pollicino C., Viney R., Haas M. Measuring health system resource use for economic evaluaton: a comparison of data sources. Aust. Health Rev. 2002, 25:171-178.
23. Portella E., Ridao M., Carrillo E., Ribas E., Ribó C., Salvat M. Alcohol y su abuso:. Impacto Socio Económico 1998, Editorial Medica Panamericana, Madrid.
24. Reijneveld S.A. The cross-cultural validity of self-reported use of health care: a comparison of survey and registration data. J. Clin. Epidemiol. 2000, 53:267-272.
25. Rychlik R., Siedentop H., Pfeil T., Daniel D. Cost-effectiveness of adjuvant treatment with acamprosate in maintaining abstinence in alcohol dependent patients. Eur. Addict. Res. 2003, 9:59-64.
26. Schadlich P.K., Brecht J.G. The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Pharmacoeconomics 1998, 13:719-730.
27. Schwappach D.L., Boluarte T.A. HEE-GER: a systematic review of German economic evaluations of health care published 1990-2004. BMC Health Serv. Res. 2007, 7:7.
28. Schwappach D.L., Boluarte T.A., Suhrcke M. The economics of primary prevention of cardiovascular disease: a systematic review of economic evaluations. CERA 2007, 5:5.
29. Shemilt I., Mugford M., Byford S., Drummond M., Eisenstein E., Knapp M., Mallender J., McDaid D., Vale L., Walker D. Incorporating economics evidence. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, Version 5.0.1 2008, Available from www.cohcrane-handbook.org (updated 2008). J.P.T. Higgins, S. Green (Eds.).
30. Stone P.W., Chapman R.H., Sandberg E.A., Liljas B., Neumann P.J. Measuring costs in cost-utility analyses. Variations in the literature. Int. J. Technol. Assess. Health Care 2000, 16:111-124.
31. UKATT Research Team Cost effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT). BMJ 2005, 331:544.
32. Walters D., Connor J.P., Feeney G.F.X., McD Young R. The cost effectiveness of naltrexone added to cognitive-behavioral therapy in the treatment of alcohol dependence. J. Addict. Dis. 2009, 28:137-144.
33. Zarkin G.A., Bray J.W., Aldridge A., Millis M., Cisler R.A., Couper D., McKay J.R., O'Malley S. The effect of alcohol treatment on social costs of alcohol dependence results from the COMBINE study. Med. Care 2010, 48:396-401.
34. Zarkin G.A., Bray J.W., Aldridge A., Mitra D., Mills M.J., Couper D.J., Cisler R.A. Cost and cost-effectiveness of the COMBINE study in alcohol dependent patients. Arch. Gen. Psychiatry 2008, 65:1214-1221.